SCHEMBL26458992

SCHEMBL26458992

Cc1cc(C)cc(N2C(=O)NC(=O)/C(=C\C=C\c3ccco3)C2=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 16/20 1.00
RECQL P46063 16/20 1.00
KMT2A Q03164 16/20 1.00
MAPT P10636 14/20 1.00
NPSR1 Q6W5P4 11/20 1.00
MAPK1 P28482 10/20 1.00
POLB P06746 10/20 1.00
MITF O75030 9/20 1.00
L3MBTL1 Q9Y468 7/20 1.00
ALDH1A1 P00352 7/20 1.00
HPGD P15428 5/20 1.00
HTT P42858 5/20 1.00
LMNA P02545 4/20 1.00
GFER P55789 3/20 1.00
NSD2 O96028 2/20 1.00
PKM P14618 6/20 0.84
ATM Q13315 1/20 0.84
XBP1 P17861 2/20 0.81
GAA P10253 1/20 0.81
SMN1; SMN2 Q16637 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1061858 0.86 KMT2A (0.75) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL1061856 0.86 KMT2A (0.75) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL2528196 0.81 MEN1 (0.76) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL12218164 0.81 MEN1 (0.76) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL3765392 0.77 MEN1 (0.67) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL3765388 0.77 MEN1 (0.67) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL14712893 0.76 MEN1 (0.74) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL30360168 0.75 EP300 (1.00) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL14181833 0.73 EP300 (0.75) MEN1RECQLKMT2AMAPTNPSR1
SCHEMBL14712884 0.73 F2 (0.78) MEN1RECQLKMT2AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MEN1 4457/4885RECQL 17/4885KMT2A 2037/4885
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MEN1 4457/4885RECQL 17/4885KMT2A 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.